Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ATOS
ATOS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ATOS News
Atossa Therapeutics Provides Strategic Update on Clinical Progress and Future Directions
4d ago
PRnewswire
Atossa Therapeutics Provides Update on Clinical Progress and FDA Feedback
4d ago
Newsfilter
Atossa Receives Rare Pediatric Disease Designation for (Z)-endoxifen
Feb 05 2026
PRnewswire
Atossa Therapeutics CEO Steven Quay Named One of Top 50 Healthcare Technology CEOs of 2025
Jan 21 2026
PRnewswire
Atossa Therapeutics CEO Steven Quay Recognized as Top 50 Healthcare Technology CEO of 2025
Jan 21 2026
Newsfilter
Atossa Therapeutics Receives FDA Orphan Drug Designation, Stock Rises Nearly 13%
Jan 20 2026
NASDAQ.COM
Atossa Therapeutics (ATOS) Receives FDA Orphan Drug Designation, Stock Rises 12.98%
Jan 17 2026
NASDAQ.COM
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen in Duchenne Muscular Dystrophy
Jan 16 2026
Newsfilter
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen in Duchenne Muscular Dystrophy
Jan 16 2026
PRnewswire
Atossa Therapeutics (ATOS) Receives FDA Orphan Drug Designation, Shares Rise 13%
Jan 16 2026
seekingalpha
Atossa Therapeutics (ATOS) Receives Orphan Drug Designation, Shares Rise 10%
Jan 16 2026
stocktwits
Atossa Therapeutics (ATOS) Shares Rise 12% on Advancing (Z)-endoxifen Program
Jan 16 2026
NASDAQ.COM
Atossa Receives FDA 'Study May Proceed' Approval for Metastatic Breast Cancer Study
Jan 06 2026
PRnewswire
Atossa Receives FDA 'Study May Proceed' Approval for Metastatic Breast Cancer Study
Jan 06 2026
Newsfilter
Atos Group Sells South American Operations to Semantix, Enhancing Strategic Focus
Dec 27 2025
NASDAQ.COM
Atossa Wins 2025 Clinical Trials Excellence Award for Advancing (Z)-Endoxifen Therapy
Dec 17 2025
PRnewswire
Show More News
